Melasma is not simply excess pigment that can be erased with a device. It is a chronic, biologically active condition influenced by ultraviolet and visible light, heat, hormones, inflammation and genetic predisposition. So, can laser treat melasma safely? In selected patients, with cautious parameters and a long-term pigment-control plan, laser treatment can have a role. Used as a quick corrective procedure without proper diagnosis, preparation or follow-up, it can provoke post-inflammatory hyperpigmentation and make the condition harder to manage.
For patients and practitioners alike, the central question is not whether a laser can lighten melasma temporarily. Many can. The clinical question is whether the proposed intervention will improve the patient’s overall pigment stability without creating rebound pigmentation, textural injury or unrealistic expectations.
Why melasma requires a different approach
Melasma commonly appears as symmetrical brown or grey-brown patches across the cheeks, forehead, upper lip and jawline. Yet its visible pattern does not reveal the full complexity of the disease. Increased melanin production is only one part of the process. Vascular activity, altered barrier function, dermal inflammation and signals from keratinocytes, fibroblasts and mast cells may all contribute.
This explains why a technically successful laser session may produce early brightening but fail to deliver durable control. If the skin is left inflamed, exposed to sunlight or treated too aggressively, melanocytes may respond by producing more pigment. In darker phototypes, and in patients with a history of post-inflammatory hyperpigmentation, that risk deserves particular weight.
A medical assessment should also establish whether the pigmentation is genuinely melasma. Solar lentigines, post-inflammatory pigmentation, lichen planus pigmentosus, drug-related pigmentation and other disorders can resemble it. Dermoscopy, Wood’s lamp examination where appropriate, a careful history and high-quality standardised photography support safer decisions than treating a brown patch on appearance alone.
Can laser treat melasma safely in the right patient?
The answer is qualified rather than absolute. Laser treatment may be considered when melasma remains troublesome despite consistent photoprotection, topical therapy and correction of modifiable triggers. It is generally best framed as an adjunct, not a replacement for medical pigment management.
Suitability depends on the patient’s skin type, pigment depth and pattern, previous inflammatory reactions, tendency to form post-inflammatory hyperpigmentation, current skincare, pregnancy or breastfeeding status, hormonal influences and capacity to follow a maintenance programme. A patient seeking a single pre-holiday procedure is rarely an ideal candidate. The period after treatment requires disciplined light avoidance and active skin protection, precisely when holidays and outdoor exposure can undermine results.
The consultation must also address expectations. Melasma can often be improved and stabilised, but it cannot reliably be described as cured. A responsible consent discussion includes the possibility of incomplete response, recurrence, temporary darkening, prolonged erythema and the need to stop treatment if the skin reacts adversely.
Device choice matters, but restraint matters more
Not all energy-based treatments carry the same risk profile. Traditional high-energy ablative resurfacing can create substantial inflammation and is usually approached with great caution in melasma-prone skin. Even when it improves pigmentation initially, the biological cost may be an increased risk of rebound.
Low-fluence, pigment-targeting approaches, including selected Q-switched Nd:YAG protocols, have been used for carefully chosen patients. Fractional non-ablative technologies may have a place where coexisting texture concerns are present, but they are not automatically safer simply because they are fractional. Picosecond devices are also used in clinical practice, yet their availability should not be confused with a guarantee of a superior or permanent outcome.
The appropriate device is only one variable. Wavelength, fluence, spot size, pulse delivery, density, cooling, treatment interval and the number of passes all influence the inflammatory burden placed on the skin. In melasma, conservative treatment parameters and a willingness to perform fewer sessions are often signs of sound clinical judgement, not therapeutic hesitation.
Test areas can be valuable, particularly for patients with deeper skin tones, previous pigment complications or uncertainty about reactivity. They do not eliminate risk, but they may reveal an undesirable inflammatory response before the entire facial area is treated.
The danger of repeated aggressive treatment
One of the more difficult scenarios in pigment practice is the patient who has undergone repeated procedures elsewhere and now presents with increasingly patchy, reactive skin. Chasing residual pigment with more energy can create a cycle of inflammation, temporary clearing and rebound darkening.
This is where the medical discipline of aesthetic practice matters most. The correct intervention may be a pause, barrier repair, withdrawal of irritating actives and restoration of photoprotection rather than another device session. Good outcomes are not measured by how much treatment is delivered. They are measured by whether the skin becomes more stable over time.
Preparation is part of treatment, not an optional extra
The safest laser protocols begin before the first pulse. Patients should have a calm, intact skin barrier and a consistent home programme. Broad-spectrum sunscreen is essential, but for melasma, protection from visible light is also relevant. Tinted formulations containing iron oxides may be particularly useful for suitable patients because visible light can worsen pigmentation in susceptible skin.
A clinician may use topical pigment-modulating treatment before and after a procedure, tailored to skin sensitivity, history and contraindications. Options can include hydroquinone under medical supervision, azelaic acid, retinoids, vitamin C, cysteamine or other established topical approaches. The correct choice is individual. Overloading an already sensitive face with multiple active products can trigger dermatitis and create precisely the pigment response the treatment is trying to avoid.
Oral treatments such as tranexamic acid require even more careful medical selection. They are not appropriate for every patient and should never be treated as a casual add-on. A history of thrombosis, clotting risk, relevant medication and wider medical factors must be assessed by a qualified prescriber.
Aftercare and follow-up protect the result
Post-treatment care should be specific and written, particularly where patients are combining prescribed topicals with active skincare purchased independently. Gentle cleansing, moisturisation, avoidance of heat exposure and suspension of potentially irritating products may be required for a defined period. Patients should know what degree of redness is expected and when they need prompt clinical review.
Follow-up photography under the same lighting conditions is more useful than memory or a single flattering mirror image. It helps the clinician distinguish genuine improvement from temporary surface brightness, identify early recurrence and decide whether maintenance therapy is preferable to further laser treatment.
For many patients, the best result is achieved with fewer energy-based procedures and stronger maintenance. That may mean ongoing photoprotection, seasonal review, topical treatment cycles and early intervention when pigment begins to reactivate. Melasma management is closer to chronic disease control than a one-off aesthetic correction.
When laser treatment should be deferred
Laser treatment should generally be postponed when there is active dermatitis, a recent sun tan, poor adherence to sun protection, unexplained pigmentation, active infection or a history suggesting severe pigmentary reactivity. Pregnancy is also a time to favour conservative management, as melasma may evolve with hormonal change and elective procedures are rarely urgent.
Caution is equally appropriate when a patient is distressed by the condition and seeking an immediate transformation. Their concern deserves empathy, but urgency can lead to overtreatment. A staged plan, with time to assess how the skin responds, is safer and more ethically defensible.
A medically led standard for pigment care
Professor Patrick Treacy’s longstanding emphasis on patient safety and biologically grounded tissue health reflects a principle that is particularly relevant to melasma: the skin should not be treated as a surface to be stripped into compliance. Pigmentary disorders demand diagnostic precision, conservative energy delivery and continuity of care.
The most useful question at consultation is therefore not, “Which laser removes melasma?” It is, “What will reduce pigment activity while preserving the health and resilience of this patient’s skin?” When that question guides assessment, treatment selection and follow-up, laser therapy can be considered responsibly - and sometimes beneficially - within a wider, medically supervised plan.